Differential (Click to cross reference) advances in neurology adverse drug reaction anemia CAT scan, abdomen cerebral infarction, hemorrhagic cerebral venous thrombosis cerebrovascular accident Clinical Pathologic Conference(C.P.C.) corneal dystrophy cost cyclophosphamide eculizumab efficacy efgartigimod alfa eye movement, painful gammaglobulin therapy, intravenous headache headache, severe hemianopia hemoglobinuria hemolysis immunosuppressive agents immunotherapy inebilizumab lactic dehydrogenase(LDH) meningismus monoclonal antibodies MRI, abnormal myasthenia gravis myasthenia gravis, drug resistant myasthenia gravis, treatment of mycophenolate neurologic disease, diagnoses of neuromyelitis optica (Devic's disease) neuromyelitis optica spectrum disorder oral contraceptives pain, abdominal paroxysmal nocturnal hemoglobinuria plasmapheresis pregnancy, neurologic complications in ravulizumab review article rituximab rozanolixizumab safety splenic-vein thrombosis splenomegaly steroid steroid sparing therapy tacrolimus thrombocytopenia treatment of neurologic disorder water channel antibodies zilucoplan

Showing articles 0 to 5 of 5 Chronic Immunotherapy for Myasthenia Gravis www.UptoDate.Com, Bird,S.J., 2024 Second Drug Okayed for Rare Central Nervous System Disease JAMA 324:224, Jaklevic, M.C., 2020 Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder NEJM 381:614-625, Pittock, S.J.,et al, 2019 Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019 Clinicopathologic Conference, Paroxysmal Nocturnal Hemoglobinuria NEJM 377:2581-2590, Case 40-2017, 2017 Showing articles 0 to 5 of 5